ABSTRACT
A surprising aspect of the development of human proteins for use as therapeutics has been the observation that many of them elicit anti-drug antibodies (ADAs) in patients. The consequences of ADA responses in the clinic vary from mild to severe. Antibodies may be transient or non-neutralizing, in which case the effects may not be adverse, although they may impact therapeutic clearance, either positively
4.1 Introduction ....................................................................................................85 4.2 T-Cell Epitope Prediction ...............................................................................88
